All In Biotech

Drug Trial Radar · NCT06237296

Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older

A Phase I, Dose-escalation, Parallel-group, Randomized, Multi-center Study to Assess Safety and Immunogenicity of an RSV/hMPV mRNA Vaccine Candidate in Healthy Participants Aged 18 to 49 Years and 60 Years and Older.

Last checked: Nov 20, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 558 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

558

Actual

Start

Jan 23, 2024

Primary completion

Feb 11, 2025

Study completion Feb 11, 2025

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Feb 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and immunogenicity an investigational messenger ribonucleic acid (mRN)A vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) and/or human metapneumovirus (hMPV) in older adults. A single intramuscular (IM) injection of 3 to 4 different doses of the RSV/hMPV mRNA vaccine candidate formulated with 2 different lipid nanoparticles (LNP) will be administered to healthy participants aged 18 to 49 years and 60 years and older. Treatment: * RSV/hMPV mRNA / LNP 1 at 3-4 different doses or, * RSV/hMPV mRNA / LNP 2 at 3-4 difference doses or, * RSV mRNA / LNP 1 at 1 dose or, * hMPV mRNA / LNP 1 at 1 dose

Conditions

  • Respiratory Syncytial Virus Infection
  • Healthy Volunteers
  • Metapneumovirus Infection

Interventions

  • RSV/hMPV mRNA LNP 1Biological

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection

  • RSV/hMPV mRNA LNP 2Biological

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection

  • RSV mRNA LNP 1Biological

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection

  • hMPV mRNA LNP 1Biological

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Presence of unsolicited systemic immediate adverse events (AEs)Time frame: Within 30 minutes after vaccination
  2. Presence of solicited injection site or systemic reactionsTime frame: Within 7 days after vaccination
  3. Presence of unsolicited AEsTime frame: Within 28 days after vaccination
  4. Presence of medically attended adverse events (MAAEs)Time frame: Throughout study (up to approximately 6 months)
  5. Presence of serious adverse events (SAEs)Time frame: Throughout study (up to approximately 6 months)
  6. Presence of adverse events of special interest (AESIs)Time frame: Throughout study (up to approximately 6 months)
  7. Presence of out-of-range biological test resultsTime frame: Within 7 days after vaccination
  8. RSV-A serum neutralizing antibody (nAb) titers at pre-vaccination (D01) and 28 days post- vaccination (D29) in the RSV/hMPV and monovalent RSV formulationsTime frame: Day 1 and Day 29
  9. RSV-B serum neutralizing antibody (nAb) titers at pre-vaccination (D01) and 28 days post- vaccination (D29) in the RSV/hMPV and monovalent RSV formulationsTime frame: Day 1 and Day 29
  10. hMPV- A serum neutralizing antibody (nAb) titers at pre-vaccination (D01) and 28 days post- vaccination (D29) in the RSV/hMPV and monovalent hMPV formulationsTime frame: Day 1 and Day 29

Locations

17 sites in 2 countries. Site status is shown where the registry gives one.

  • Velocity Gardena Site Number : 8400011

    Gardena, California

  • Velocity Clinical Research-Hallandale Beach- Site Number : 8400013

    Hallandale, Florida

  • Advanced Clinical Research- Site Number : 8400005

    Meridian, Idaho

  • Velocity Clinical Research, Sioux City Site Number : 8400017

    Sioux City, Iowa

  • Velocity Clinical Research- New Orleans Site Number : 8400016

    New Orleans, Louisiana

  • Meridian Clinical Research- Site Number : 8400007

    Binghamton, New York

  • Velocity Clinical Research- Site Number : 8400012

    Cleveland, Ohio

  • Coastal Carolina Research Center- Site Number : 8400001

    North Charleston, South Carolina

  • Charlottesville Medical Research Center Winding River - Site Number : 8400002

    Charlottesville, Virginia

  • Investigational Site Number : 0360007

    Canberra, Australia

  • Investigational Site Number : 0360006

    Blacktown, New South Wales, Australia

  • Investigational Site Number : 0360002

    Botany, New South Wales, Australia

  • Investigational Site Number : 0360003

    Kanwal, New South Wales, Australia

  • Investigational Site Number : 0360004

    Sydney, New South Wales, Australia

  • Investigational Site Number : 0360008

    Herston, Queensland, Australia

  • Investigational Site Number : 0360005

    Morayfield, Queensland, Australia

  • Investigational Site Number : 0360001

    Camberwell, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.